EAU 2013 - Programme Book - YouMed

Saturday, 16 March - EAU Programme
Abstract Session
08.30 - 10.00 Urothelial cancer: Tumour biology and experimental therapies
Silver Hall - Level N2
Poster Session 5
Chairs: M. Knowles, Leeds (GB)
D. Theodorescu, Aurora (US)
Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes
in length, followed by 2 minutes for discussion. Extended presentations (*) are 4 minutes in length, followed
by 2 minutes for discussion.
* 50 Silencing Notch-1 and Notch-3 promotes epithelial-to-mesenchymal transition (EMT) and self-renewal
potential in human bladder cancer
W. Jaeger, T. Hayashi, S. Awrey, K.M. Gust, T. Cordonnier, N. Li, R. Buttyan, T.H. Van Der Kwast, B.W. Van
Rhijn, J.W. Thüroff, P.C. Black (Vancouver, Toronto, Canada; Frankfurt, Mainz, Germany; Amsterdam, The
Netherlands)
51 Epigenetic alterations associated with neo-adjuvant chemotherapy resistance in bladder cancer
A. Feber, W.S. Tan, P. De Winter, A. Freeman, K. King, P. Gurung, C. Jameson, R. Bryan, N. James, S. Beck,
J. Kelly (London, United Kingdom)
52 MicroRNA expression signatures in bladder cancer: MicroRNA-145 function as a tumor suppressor and its
mediated cancer pathways
H. Yoshino, N. Seki, H. Hidaka, T. Yamasaki, T. Idesako, H. Enokida, M. Nakagawa (Kagoshima, Chiba, Japan)
53 A ‘4-miR’ signature in urine identifies recurrent bladder cancer in patients undergoing surveillance
N. Sapre, H. Lewis, G. Macintyre, A. Kowlaczyk, A.J. Costello, N.M. Corcoran, C.M. Hovens (Melbourne,
Australia)
54 Validation of TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic bladder cancer markers
W. Beukers, R. Kandimalla, R. Masius, M. Vermeij, E.C. Zwarthoff (Rotterdam, The Netherlands)
55 Circulating tumor cells and their prognostic significance in non-muscle invasive bladder cancer: A cell
search analysis
G.M. Busetto, A. Gradilone, C. Nicolazzo, A. Petracca, P. Gazzaniga, V. Gentile, E. De Berardinis (Rome, Italy)
56 Specific changes in the DNA methylation pattern enable an early assessment of the metastatic risk of
primary bladder tumours
B. Stubendorff, K. Wilhelm, S. Dubey, E. Dudziec, J.W.F. Catto, M. Gajda, M-O. Grimm, K. Junker (Jena,
Homburg, Germany; Oxford, Sheffield, United Kingdom)
57 Ritonavir and bortezomib inhibit bladder cancer growth by inducing endoplasmic reticulum stress and
ubiquitinated protein accumulation synergistically
A. Sato, T. Asano, K. Ito, T. Asano (Tokorozawa, Japan)
58 DNA damage response (DDR) genes are predictive of response to radiotherapy for muscle invasive bladder
cancer
P.M.S. Gurung, N. Counsell, J. Douglas, W. Tan, A. Feber, S. Short, S. Crabb, C. West, P. Hoskin, L. Beltran,
A. Freeman, T. Powles, J. Kelly (London, Southampton, Leeds, Manchester, United Kingdom)
59 Enhancement of γδ T cell antitumor activity against bladder cancer cell through 4-1BB and PD-1 mediated
activation
T. Suzuki, H. Yoshihide, K. Akihiro, N. Michio, Y. Shingo (Nishinomiya, Japan)
EAU Milan 2013
85
Saturday